LONDON, March 21, 2016 /PRNewswire/ -- This BCC Research report provides an up-to-date analysis of recent developments and current trends in the global erythropoietin drug market. Includes forecast through 2020.
Use this report to:
Gain information about the various types applications of erythropoietin stimulating agents.
Analyze current trends within the industry, major industry challenges, and the regional dynamics of the global erythropoietin drug market.
Quantify the projected impact of both internal and external forces affecting the global erythropoietin drug market today and over the next several years.
Analyze detailed profiles of major vendors in the erythropoietin drug industry globally.
The global market for erythropoietin stimulating agents (ESAs) will grow from nearly $7.2 billion in 2015 to nearly $7.3 billion by 2020 with a compound annual growth rate (CAGR) of 0.2% for the period 2015-2020.
The Epoetin-alfa drug market is the largest segment and should reach approximately $3.3 billion in 2015 and nearly $2.1 billion by 2020, a CAGR of -8.4%.
The Epoetin-omega drug market is expected to increase from nearly $371.8 million in 2015 to nearly $1.1 billion in 2020, a CAGR of 23.3%.
The global market for erythropoietin drug can be broadly classified into two segments:
biologics and biosimilars.
The major types of biologic erythropoietin drugs based on different biological properties are epoetin-alfa, epoetin-beta, darbepoetin-alfa and epoetin-theta.
The major types of biosimilar erythropoietin drug based on the different biological properties are epoetin-zeta, epoetin-omega, epoetin-lambda and epoetin-delta.
The global erythropoietin biologics drug market has been growing in terms of value from the past 15 years in pace with the increasing prevalence of chronic kidney diseases throughout the world, however the market is expected to see decline in the forecast period due to expiry of major patented drugs in the U.S. and European markets; and due to the entrant of many biosimilar erythropoietin drug in the European market since 2008 which are approximately 20% to 30% cheaper compared to patented drug.
The global erythropoietin biosimilars drug market has been growing rapidly in the last decade years, primarily due to the patent expiry of major erythropoietin biologic drug in European market and demand for cheaper priced erythropoietin drugs in the Asia-Pacific, South America, Middle-east and African market. The study covered in this
report has been conducted to analyze and quantify the emerging market opportunities for erythropoietin drug, as well as to highlight the key current research efforts that are driving erythropoietin drug into new applications. In addition, major players of the erythropoietin drug, along with their upcoming and anticipated erythropoietin-related
products are analyzed to demonstrate how these advances might impact global erythropoietin drug market.
The application of erythropoietin drug is divided broadly into three types: chronic kidney diseases; oncology diseases; and other applications such as treatment of anemia in HIV patients. The key drivers for the erythropoietin drug market are increasing case of chronic disease and increasing prevalence of cancer.
Amgen Inc., Hoffmann-La Roche and Johnson & Johnson are some of the key players of biologics erythropoietin drug market. Sandoz (subsidiary of Novartis International AG), Hospira (subsidiary of Pfizer Inc.), 3SBio, BioSidus and Teva Pharmaceutical Industries Ltd. are some of the major players of biosimilar erythropoietin drugs market.
The market for erythropoietin in Asia-Pacific and South America is expected to grow at the fastest rate compared to other global markets, which are expected to decline. The entrant of erythropoietin biosimilars drugs in Europe and the U.S. will create a huge impact during the forecast period, resulting in a decline in the global erythropoietin drug market.
Download the full report: https://www.reportbuyer.com/product/3479639/
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
For more information:
Research Advisor at Reportbuyer.com
Tel: +44 208 816 85 48
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/erythropoietin-stimulating-agents-therapeutic-applications-and-global-markets-300239245.html